Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Gen ADC Program in Oncology
“We are excited to collaborate with MediLink on this program. We will leverage our capabilities to advance the global development of YL212,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development at Zai Lab. “This collaboration demonstrates our continued focus on developing cancer therapies including ADC drugs, further enriching our global oncology pipeline. It also complements our existing strong lung cancer portfolio. YL212 is advancing rapidly to the clinical stage, and we look forward to testing this compound in patients with limited therapeutic options.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome